4d • General discussion
Survodutide (BI 456906):
NOW AVAILABLE AT JADE NEXUS
40% OFF 💥INCLUDING VIAL SETS💥 WITH CODE: KRISTINA
Survodutide is an investigational once-weekly peptide that acts as a dual GLP-1 receptor and glucagon receptor agonist. Unlike Tirzepatide (GLP-1/GIP), Survodutide combines appetite suppression from GLP-1 with increased energy expenditure and fat metabolism from glucagon receptor activation.
Potential Benefits:
1. Significant Weight Loss
In clinical trials, participants achieved approximately 16–19% average body weight reduction, placing Survodutide among the more effective obesity medications currently in development.
2. Reduction in Visceral ("Belly") Fat
Survodutide appears particularly effective at reducing visceral adipose tissue, the metabolically harmful fat surrounding organs. MRI analyses demonstrated reductions of up to 34% in visceral fat.
3. Dramatic Liver Fat Reduction
One of survodutide's most impressive findings has been its impact on fatty liver disease.
Clinical studies have shown:
- Up to 63% reduction in liver fat
- Improvement in markers of liver inflammation and fibrosis
- Potential benefit for MASLD/MASH patients
4. Preservation of Lean Mass
Unlike some weight-loss therapies where muscle loss can be significant, survodutide appears to preserve lean body mass relatively well while preferentially reducing fat mass.
5. Cardiometabolic Improvements
Studies have demonstrated improvements in:
- Blood glucose
- Insulin sensitivity
- Lipid markers
- Cardiovascular risk factors
- Liver enzymes
********************************************************************************************************
10mg vial + 2.0mL bac water
Concentration: 5mg/mL
Week 1-4 0.6 mg weekly (12 units)
Week 5-8 1.2 mg weekly (24 units)
Week 9-12 1.8 mg weekly (36 units)
Week 13-16 2.4 mg weekly (48 units)
Week 17-20 3.0 mg weekly (60 units)
Week 21-24 3.6 mg weekly (72 units)
Week 25-28 4.8 mg weekly (96 units)
Maintenance 6.0 mg weekly (120 units)
*********************************************************************************************************
Common Side Effects:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Reduced appetite
- Fatigue
- Gastrointestinal discomfort
These effects are generally most noticeable during dose escalation.
Current data suggest Tirzepatide may still have a slight edge for total weight loss, while Survodutide may offer unique advantages for visceral fat, liver fat, and metabolic liver disease.
Survodutide is often best described as "the GLP-1 that may burn fat from both directions—by reducing intake and potentially increasing energy expenditure." This is what has researchers particularly excited about its future potential.
11
1 comment
Survodutide (BI 456906):
skool.com/peptidejunkies24
Advance your peptide research with precise, science-driven guidance, expert community talk, and access to vetted suppliers, promotions, and giveaways.
Leaderboard (30-day)
1
+10
2
+10
3
+9
4
+9
5
🔥
+6
Powered by